Chemical Biology, Merck & Co., Inc, Boston, MA 02115, USA.
Chemical Biology, Merck & Co., Inc, Boston, MA 02115, USA.
Cell Chem Biol. 2022 Nov 17;29(11):1639-1648.e4. doi: 10.1016/j.chembiol.2022.10.008. Epub 2022 Nov 9.
DNA-binding proteins are promising therapeutic targets but are notoriously difficult to drug. Here, we evaluate a chemoproteomic DNA interaction platform as a complementary strategy for parallelized compound profiling. To enable this approach, we determined the proteomic binding landscape of 92 immobilized DNA sequences. Perturbation-induced activity changes of captured transcription factors in disease-relevant settings demonstrated functional relevance of the enriched subproteome. Chemoproteomic profiling of >300 cysteine-directed compounds against a coverage optimized bead mixture, which specifically captures >150 DNA binders, revealed competition of several DNA-binding proteins, including the transcription factors ELF1 and ELF2. We also discovered the first compound that displaces the DNA-repair complex MSH2-MSH3 from DNA. Compound binding to cysteine 252 on MSH3 was confirmed using chemoproteomic reactive cysteine profiling. Overall, these results suggested that chemoproteomic DNA bead pull-downs enable the specific readout of transcription factor activity and can identify functional "hotspots" on DNA binders toward expanding the druggable proteome.
DNA 结合蛋白是很有前途的治疗靶点,但很难用药物进行靶向治疗。在这里,我们评估了一种化学蛋白质组学 DNA 相互作用平台,作为并行化合物分析的补充策略。为了实现这一方法,我们确定了 92 个固定化 DNA 序列的蛋白质组结合图谱。在与疾病相关的环境中,捕获的转录因子的扰动诱导活性变化证明了富集亚蛋白组的功能相关性。针对优化覆盖率的珠子混合物(特异性捕获 >150 个 DNA 结合蛋白)进行的 >300 种半胱氨酸导向化合物的化学蛋白质组学分析揭示了包括转录因子 ELF1 和 ELF2 在内的几种 DNA 结合蛋白的竞争。我们还发现了第一种能够将 DNA 修复复合物 MSH2-MSH3 从 DNA 上置换下来的化合物。使用化学蛋白质组学反应性半胱氨酸分析证实了化合物与 MSH3 上的半胱氨酸 252 的结合。总的来说,这些结果表明,化学蛋白质组学 DNA 珠下拉技术能够特异性地检测转录因子的活性,并能确定 DNA 结合蛋白上针对扩大可药物靶蛋白组的功能“热点”。